Europe - Frankfurt Stock Exchange - FRA:LLY - US5324571083 - Common Stock
Overall LLY gets a fundamental rating of 6 out of 10. We evaluated LLY against 55 industry peers in the Pharmaceuticals industry. While LLY has a great profitability rating, there are some minor concerns on its financial health. LLY shows excellent growth, but is valued quite expensive already. This makes LLY very considerable for growth investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| ROIC | 28.84% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.41% | ||
| PM (TTM) | 30.99% | ||
| GM | 83.03% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | 6.6 | ||
| Altman-Z | 8.36 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.24 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.21 | ||
| Fwd PE | 30.66 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 149.21 | ||
| EV/EBITDA | 36.52 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.64% |
ChartMill assigns a fundamental rating of 6 / 10 to LLY.DE.
ChartMill assigns a valuation rating of 3 / 10 to ELI LILLY & CO (LLY.DE). This can be considered as Overvalued.
ELI LILLY & CO (LLY.DE) has a profitability rating of 9 / 10.
The Price/Earnings (PE) ratio for ELI LILLY & CO (LLY.DE) is 46.21 and the Price/Book (PB) ratio is 40.36.
The Earnings per Share (EPS) of ELI LILLY & CO (LLY.DE) is expected to grow by 84.93% in the next year.